Welcome to our dedicated page for MindWalk Holdings news (Ticker: HYFT), a resource for investors and traders seeking the latest updates and insights on MindWalk Holdings stock.
MindWalk Holdings Corp. reports developments in Bio-Native AI drug discovery, biologics research, and AI-driven therapeutic development. Company updates center on its patented HYFT technology and LensAI platform, which combine biological sequence, structure, function, literature analysis, and wet-lab validation for biologics discovery workflows.
Recurring news themes include financial results, enterprise platform contracts, North American biologics services activity, and product or program updates. Announcements have covered B Cell Llama for VHH nanobody discovery, B Cell Select, universal influenza research, functional-adjacency analysis for AI-designed therapeutics, and antibody or intrabody discovery work involving pathogenic TDP-43 in neurodegenerative disease.
MindWalk (Nasdaq: HYFT) reported preclinical dengue data supporting a HYFT® computational prediction. HYFT® identified a candidate pan-serotype dengue target before immunization; immunogens designed on this target elicited antibodies that cross-reacted with antigens from all four dengue serotypes, reproduced across two independent campaigns. Scrambled controls lacked similar cross-serotype recognition, indicating specificity to the designed immunogen.
The experimentally supported target now anchors MindWalk's dengue pipeline IP within its Biointelligence Platform, and the same predictive capability is being applied to influenza and other multi-strain infectious disease programs.
MindWalk Holdings (NASDAQ: HYFT) launched its Pandemic Response Platform, a HYFT® and LensAI™ configuration for outbreak preparedness and rapid countermeasure design against RNA viruses, announced May 27, 2026.
The platform targets conserved viral architecture instead of mutable surface proteins and is already deployed on wholly owned pan-serotype Dengue and universal Influenza programs at in vivo proof-of-concept stage. It builds on an infrastructure that has supported over 20 molecules advanced to the clinic and uses The Knowledge Graph with 660 million biological patterns and 25 billion relationships to identify structurally constrained targets across evolving RNA virus families.
MindWalk Holdings (NASDAQ: HYFT) reported that over 20 drug candidates in partner pipelines originated from its antibody discovery work, with 10 programs now in active Phase 1–3 clinical trials across oncology, immunology, neurology, and infectious disease.
The company highlighted its HYFT® and LensAI™ biological intelligence infrastructure, built on a Knowledge Graph indexing 660 million biological patterns and 25 billion relationships, and a record of 400+ peer-reviewed publications and patents supporting collaborations with firms such as Annexon, argenx, Xencor, Cullinan Oncology, and others.
MindWalk Holdings (Nasdaq: HYFT) reported Q3 fiscal 2026 revenue of $4.2 million, a 52% increase year‑over‑year, marking the third consecutive quarterly YoY revenue gain. US revenue doubled to $2.6 million. Gross margin was 59% in Q3 and cash totaled $14.2 million as of Jan 31, 2026.
The company signed its first one‑year recurring LensAI platform contract, launched the B cell Llama nanobody platform, reported progress on dengue, GLP‑1 and influenza programs, and is designing asset‑level financing for select assets.
MindWalk Holdings (NASDAQ: HYFT) announced B Cell Llama™, a VHH nanobody discovery platform built for bispecific, multispecific and cell therapy development. A peer-reviewed 2026 study in Biomacromolecules showed multivalent VHH formats reached sub-nanomolar potency and 10–25x activity versus monovalent forms.
The study found a trivalent construct neutralized variants that escaped monovalent molecules and suggested a possible immune-priming effect. MindWalk holds first right to commercialize jointly developed IP and will layer LensAI™ to prioritize functional activity over binding metrics.
MindWalk Holdings Corp (NASDAQ:HYFT) will report third quarter fiscal 2026 results and host a live conference call and webcast on March 12, 2026 at 10:30 AM ET. Financial results will be released prior to the call and followed by a management presentation and Q&A.
Live and replay access will be available via the company’s investor events page, with participant dial-in details and conference ID provided for telephone access.
MindWalk (NASDAQ:HYFT) applied its proprietary HYFT® functional‑intelligence technology to detect “functional adjacency” — distinct molecules that produce the same therapeutic effect despite low sequence similarity. Using an influenza study, HYFT identified a conserved biological signature that persists across viral mutation, supporting broader vaccine target design and exposing competitive/IP risks that sequence alignment can miss. MindWalk positions HYFT as a scalable platform to assess functional overlap for discovery, diligence, patent strategy, and portfolio risk as AI accelerates protein design.
MindWalk (Nasdaq: HYFT) announced discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic TDP-43, a protein implicated in ALS, frontotemporal dementia and some Alzheimer’s disease cases. The work shows the company’s platform can distinguish toxic protein conformations from healthy forms and anchors those findings with bio-native wet-lab validation. MindWalk says this validates its platform strategy and reinforces its position as a discovery partner for complex neurodegenerative programs. The study is available on bioRxiv (DOI: 10.1101/2025.06.10.658846).
MindWalk (NASDAQ:HYFT) reports a functional insight in its universal influenza program: a HYFT-defined functional constraint observed across influenza A and B despite sequence variation. MindWalk says this pattern was validated in human H3N2 (including subclade K), avian H5/H7/H9, swine H1N1, and influenza B (Victoria and Yamagata). The company plans further pre-clinical validation and IND-enabling work within a segregated program portfolio, then aims to out-license or partner for late-stage development.
MindWalk (NASDAQ:HYFT) announced a discovery of a persistent functional constraint in influenza biology identified using its patented HYFT Deep Data technology. The company reports the HYFT-defined pattern is conserved across human influenza A (including H3N2 and H3N2 subclade K), avian A subtypes H5, H7, H9, swine-origin H1N1, and influenza B lineages Victoria and Yamagata. MindWalk says this constraint reflects biophysical requirements for infection rather than conserved sequence, and plans further preclinical and IND-enabling work with an out-licensing or strategic-partnering strategy for the program.